Clinical Trial Search

Primary: Number of Participants Who Achieved a Raymond Score I/II or Experienced Neurological Death — 0; 29 Participants

Primary: mITT Primary Effectiveness Endpoint. Based on Subjects With 100% Occlusion of the Aneurysm Without Clinically Significant Stenosis of the Parent Artery, and Without Any…

Primary: Number of Participants With Neurologic Death or Major Ipsilateral Stroke Within 12 Month Follow-up Period. — 5 Participants

Primary: Number of Participants With the Occurrence of Major Ipsilateral Stroke or Neurologic Death and Occurrence of Ipsilateral Stroke or Neurologic Death. — 6; 10 Participants…

Primary: The Percentage of Participants With the Occurrence of Major Stroke in the Territory Supplied by the Treated Artery or Neurological Death at 12-Months Post Procedure…

Primary: Number of Participants With Raymond Class I Complete Obliteration at 12 Months — 98 Participants

Primary: Stroke or Death in the Territory of Qualifying Artery — 5 Participants — p=0.08

Primary: Any Stroke or Death Within 30 Days of Enrollment or Any Revascularization Procedure OR an Ischemic Stroke in the Territory of the Symptomatic Intracranial Artery Beyond…

Primary: The Primary Safety Endpoint Included Any Death or Major Stroke in the First 30 Days and Neurologic Death or Ipsilateral Major Stroke Between Day 31 and Day 365. — 1…

Primary: Technical Feasibility- Successful Stent/Coil Placement (Post Procedure) — 100; 90 percentage of stable placement

Primary: Percentage of Participants With Major Adverse Cardiac Events(MACE) — 1.72; 6.86 percentage of participants

Primary: Progression-free Survival (PFS) — 91.3 percentage of participants

Primary: Number of Patients With Freedom From Patency-related Intervention Defined as a Secondary Intervention to Treat a > 60 % Stenosis of the Internal Iliac Artery Associated…

Primary: Number of Participants With Target Vessel Failure (TVF) at 30 Days Post Procedure. — 2 Participants

Primary: Primary Safety Endpoint: Percentage of Participants With Death of Any Non-accidental Cause or Major Disabling Stroke Within First 30 Days After Treatment or Major…

Primary: Percentage of Participants With Complete Occlusion of the Target Aneurysm and ≤50% Stenosis of the Parent Artery and an Alternative Treatment of the Target Intracranial…

Primary: Procedural Success — 91.4 percentage of participants

Primary: Prognostic Value of the MAFA (Mean Aneurysm Flow Amplitude) Ratio With Respect to Full Aneurysm Occlusion Within 12 Months — 0.540 probability

Primary: Change in Montreal Cognitive Assessment (MoCA) Score — 0.56; 1.38; -0.75; 0.50 score on a scale

Primary: Volume of New FLAIR Lesions(MRI) — 915; 477 mm^3 — p=0.445

Primary: ICG Fluorescence Ratio — 0.92; 0.82 Ratio

Primary: Freedom From Aneurysm Rupture — 22 Participants

Primary: Number of Participants With Successful Study Device Access — 9 Participants

Primary: Target Volume Difference Between Standard of Care vs. CT Angiogram and MRI Alone — 1.1; 1.3 mL

Primary: Change in Radiation Necrosis and Cerebral Edema After a Single Treatment of Low Dose Intra-arterial Avastin (Bevacizumab) — 86.8; 38.6; 32.6; 14.5 cm^3 — p=0.012

Primary: Primary Safety Endpoint (Freedom From MAEs Within 30 Days of Index Procedure) — 88.6; 96.0 percentage of participants

Primary: Probable Benefit Measures as Successful Aneurysm Treatment With the LVIS™ Device, as Measured by Aneurysm Angiographic Occlusion of ≥ 90% at 6 Months (± 4 Weeks) — 95…

Primary: Absence of the Following Procedural Safety Events: Death, Stroke, Myocardial Infarction, Bowel Ischemia, Paraplegia, Respiratory Failure, Renal Failure, Procedural Blood…

Primary: Residual or Re-accumulation of the Chronic Subdural Hematoma (cSDH) (Greater Than [>] 10 Millimeter [mm]) as Assessed by an Independent Core Laboratory OR Any…

Primary: Percentage of Regions With Collateral Versus Antegrade Blood Flow (Sensitivity) Correctly Identified Using MRI With Xenon Contrast Agent (Specificity) — 81.7; 88.9…